Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Therapy||Indication/Tumor Type||Response Type||Profile Response Detail|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02798536||Phase I||LMB-100 LMB-100 + Nab-paclitaxel||Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma||Completed||USA||0|
|NCT02810418||Phase Ib/II||LMB-100 LMB-100 + Nab-paclitaxel||Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors||Completed||USA||0|
|NCT03319537||Phase Ib/II||MLN4924 Cisplatin + MLN4924 + Pemetrexed Disodium||Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma||Active, not recruiting||USA||0|
|NCT03436732||Phase I||LMB-100 + SVP-rapa||Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma||Terminated||USA||0|
|NCT03507452||Phase I||BAY2287411||First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin||Completed||USA||4|
|NCT04034238||Phase I||LMB-100 + Tofacitinib||Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors||Active, not recruiting||USA||0|
|NCT05041062||Phase II||Ipilimumab + Nivolumab||A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma||Recruiting||USA||0|